Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1035736 | 0.80 | TLR9 (0.67) | TLR9ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1035737 | 0.80 | TLR9 (0.67) | TLR9ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL10150411 | 0.80 | TLR9 (0.67) | TLR9ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2787588 | 0.78 | TLR9 (0.80) | TLR9ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1344341 | 0.78 | TLR9 (0.80) | TLR9ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL7541319 | 0.78 | TLR9 (0.64) | TLR9ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1344338 | 0.78 | TLR9 (0.80) | TLR9ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL343050 | 0.77 | TLR9 (0.70) | TLR9ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL7124038 | 0.76 | TLR9 (0.61) | TLR9ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL758697 | 0.75 | CA2 (0.50) | TLR9CA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1056 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230018780-A1 | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND | NIPPON SHINYAKU CO., LTD. (JP) | 2023-01-19 | — | — | US | claimed |
| US-20230014840-A1 | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND | NIPPON SHINYAKU CO., LTD. (JP) | 2023-01-19 | — | — | US | claimed |
| CN-114981281-A | Method for producing oligonucleotide compound | 日本新药株式会社 | 2022-08-30 | — | — | CN | claimed |
| CN-114981280-A | Method for producing oligonucleotide compound | 日本新药株式会社 | 2022-08-30 | — | — | CN | claimed |
| WO-2021095874-A1 | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND | 日本新薬株式会社 | 2021-05-20 | — | — | WO | claimed |
| WO-2021095875-A1 | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND | 日本新薬株式会社 | 2021-05-20 | — | — | WO | claimed |
| US-20210024919-A1 | FUNCTIONALIZED SOLID SUPPORT | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2021-01-28 | — | — | US | claimed |
| US-20200256862-A1 | FUNCTIONALIZED SOLID SUPPORT | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2020-08-13 | — | — | US | claimed |
| US-8846898-B2 | Phosphinoamidite carboxylates and analogs thereof in the synthesis of oligonucleotide having reduced internucleotide charge | Lieure Cornu LLC (US) | 2014-09-30 | — | — | US | claimed |
| EP-2066662-B1 | SERINE HYDROLASE INHIBITORS | KYORIN SEIYAKU KK (JP) | 2012-12-05 | — | — | EP | claimed |
| EP-0920414-A1 | MATRIX METALLOPROTEINASE INHIBITORS | PHARMACIA & UPJOHN S.p.A. (IT) | 1999-06-09 | — | — | EP | claimed |
| WO-1999014238-A1 | PROCESS FOR THE PREPARATION OF CALCITONIN | HYUNDAI PHARM. IND. CO., LTD. (KR) | 1999-03-25 | — | — | WO | claimed |
| WO-1999002510-A1 | MATRIX METALLOPROTEINASE INHIBITORS | PHARMACIA & UPJOHN S.P.A. (IT) | 1999-01-21 | — | — | WO | claimed |
| US-5859256-A | CHLORINATION; USEFUL AS ANTIBACTERIAL AGENTS AND IN TREATING DISEASES CAUSED BY ORGANISMS WHICH ARE RESISTANT TO BETA-LACTAM ANTIBIOTICS | MICROCIDE PHARMACEUTICALS, INC. (US) | 1999-01-12 | — | — | US | claimed |
| EP-0874854-A2 | CEPHALOSPORIN ANTIBIOTICS | Microcide Pharmaceuticals, Inc. (US) | 1998-11-04 | — | — | EP | claimed |
| WO-1997049674-A1 | MATRIX METALLOPROTEINASE INHIBITORS | PHARMACIA & UPJOHN S.P.A. (IT) | 1997-12-31 | — | — | WO | claimed |
| WO-1997013772-A2 | CEPHALOSPORIN ANTIBIOTICS | MICROCIDE PHARMACEUTICALS, INC. (US) | 1997-04-17 | — | — | WO | claimed |
| EP-0635500-A1 | 5,6-Dihydro-(4H)1,3-oxazine and -thiazine derivatives as insecticides | YASHIMA CHEMICAL INDUSTRY CO., LTD. (JP) | 1995-01-25 | — | — | EP | claimed |
| EP-0006693-A1 | N-substituted trialkylstannylhydrocarbylcarboxylic acid hydrazides, methods of their preparation and insecticide compositions containing them | UNIROYAL, INC. (US) | 1980-01-09 | — | — | EP | claimed |
| US-4178382-A | INSECTICIDE FOR COTTON | UNIROYAL, INC. (US) | 1979-12-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230018780-A1 | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND | POLRMT, POLR2H, POLM | TLR9 1780/4885ALDH1A1 3846/4885CYP1A2 4633/4885 |
| US-20230014840-A1 | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND | DNASE1, XRN2, FBL | TLR9 1775/4885ALDH1A1 979/4885CYP1A2 2387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.